FY2026 Q3 Financial Summary [IFRS] (Consolidated)

Performance Overview

For FY2026 Q3 consolidated results, revenue was 397.0 billion yen (6.0% YoY increase), operating income was 88.2 billion yen (24.8% YoY increase), profit before income taxes for the quarter was 89.4 billion yen (24.1% YoY increase), and quarterly profit was 68.9 billion yen (21.8% YoY increase). On a core basis, revenue was 397.0 billion yen (6.0% increase), core operating income was 116.3 billion yen (19.1% increase), and core quarterly profit was 89.9 billion yen (17.6% increase), achieving profit growth. Key products contributing to growth included the diabetes, chronic heart failure, and chronic kidney disease treatment 'Forxiga Tablets,' which recorded revenue of 72.7 billion yen, a 5.7% increase year-on-year.

Financial Position and Cash Flow Status

Total assets amounted to 1.0844 trillion yen, an increase of 20.4 billion yen from the previous fiscal year-end, and equity attributable to owners of the parent also rose by 57.2 billion yen to 839.7 billion yen. Cash and cash equivalents at the end of the period were 188.3 billion yen, up compared to the same period last year. Cash flow from operating activities was an inflow of 86.6 billion yen, outflows from investing activities were 44.0 billion yen, and outflows from financing activities were 59.8 billion yen.

Outlook

There is no change to the full-year earnings guidance announced on October 30, 2025. Full-year revenue is projected at 490.0 billion yen (0.6% YoY increase), operating income at 85.0 billion yen (42.3% YoY increase), and net income at 67.0 billion yen (33.6% YoY increase).